Oncology-Prostate Cancer Independent Medical Education Grant
Forecasted
AstraZeneca United States funds education programs to advance clinical understanding of metastatic hormone sensitive prostate cancer and new therapies through the Oncology-Prostate Cancer Independent Medical Education Grant.
Funder: AstraZeneca United States
Due Dates (Anticipated): August 2027 (Full application deadline, 9 AM EST, projected)
Funding Amounts: Up to $300,000 per program; typically supports single-year, accredited educational initiatives.
Summary: Supports independent, accredited education programs for healthcare professionals on metastatic hormone sensitive prostate cancer and emerging therapies.
Description
This grant opportunity from AstraZeneca United States funds independent medical education initiatives focused on metastatic hormone sensitive prostate cancer (mHSPC). The aim is to address unmet educational needs among healthcare professionals regarding new and emerging therapies, such as ARPIs combined with targeted agents (e.g., PARP inhibitors). Programs should promote evidence-based understanding of clinical and molecular markers, sequencing, resistance, and long-term tolerability, ultimately improving patient care and outcomes in this rapidly evolving field.
